4.14
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com India
Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com South Africa
Moleculin Biotech Reports Positive Phase 1 Trial Results for WP1066 in Pediatric Brain Cancer Treatments - Quiver Quantitative
Moleculin Biotech, Inc. Announces Positive Phase 1 Trial Results for WP1066 - TradingView — Track All Markets
Moleculin Announces Positive Results from Phase 1 Clinical - GlobeNewswire
Moleculin Biotech regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Nigeria
Moleculin Biotech Regains Nasdaq Compliance - TipRanks
Moleculin Biotech regains compliance with Nasdaq minimum bid price rule - Investing.com India
Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
CapEx per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView — Track All Markets
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus
HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq
Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters Inducement Offer Agreements - TipRanks
Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com South Africa
Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India
Moleculin Biotech raises $6.5 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative
Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan
Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io
Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus
Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks
Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria
Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView — Track All Markets
Moleculin stock rises as AML trial enrollment reaches 78% - Investing.com
Moleculin reports 78% enrollment in AML treatment trial - Investing.com
Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com South Africa
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal 'MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - The Manila Times
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm
Moleculin Announces Completion of Treatment for the 45 - GlobeNewswire
The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews
Moleculin (Nasdaq: MBRX) Tracks Toward 45-Patient MIRACLE AML Readout in Q1 2026 - Stock Titan
Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com Australia
After tax other income/expense of Moleculin Biotech, Inc. – BER:MOL0 - TradingView — Track All Markets
Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks
Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus
大文字化:
|
ボリューム (24 時間):